Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New point system enhances prognosis for GIST patients

07.02.2005


A research team at the Sahlgrenska Academy at Göteborg University in Sweden has developed a point system for calculating risk that will help physicians determine prognoses, survival rates, and the best methods of treatment for patients suffering from GIST tumors. The findings are being published in the prestigious medical journal Cancer.



GIST is a soft tissue tumor that occurs in the abdomen but differs from gastro-intestinal cancer. Nearly two hundred Swedes are affected every year. Long-term survival rates have been low. GIST tumors can grow very large and occupy a major section of the abdomen. Some tumors weigh as much as five kilos. For many years the only method of treatment was surgery, but over the last four years it is has been possible to combine surgery with new medicinal treatment in the form of the medicine Imatinib. The medicine is administered to inhibit the growth of the tumor and to prevent the emergence of new tumors and metastases.

Of all GIST patients, 44 percent develop highly aggressive tumors that in many cases are fatal. These patients should receive priority for medicinal treatment. The new medicine Imatinib is the first drug that effectively treats patients with malignant GIST.


“GIST tumors have been under-diagnosed. Therefore there is a great risk that patients will not receive optimal treatment. The development of Imatinib offers the first effective medicinal treatment of aggressive GIST. Therefore it has become absolutely essential for pathologists, surgeons, and oncologists to be able to diagnose this tumor correctly and to determine just how aggressive the tumor is in order to provide the best possible care,” says Professor Lars-Gunnar Kindblom, who directed the present study together with Professor Jeanne Meis-Kindblom and Associate Professor Bengt Nilsson.

On the basis of a unique study of all GIST cases in Western Sweden between the years 1983 and 2000, Lars-Gunnar Kindblom’s research team developed a system of points. Using this system it is possible to determine a patient’s prognosis in terms of both survival and the risk of developing new tumors. The system is based how large the tumor is and how quickly it is growing, which is determined by analyzing tissue samples.

The scientists divided the GIST patients into four groups­-extremely low risk, low risk, moderate risk, and high risk­-on the basis of the size of the tumor and an index that calculates how many cells are dividing. Of the 170 patients with GIST tumors classified as extremely low risk, low risk, and moderate risk, only one patient had a tumor that could not be operated on, and three patients had recurrent tumors. This can be compared with the 89 patients with high-risk tumors, among whom 36 had inoperable tumors and 35 developed new tumors after surgery. Among patients with high-risk tumors, 63 percent died as a result of their GIST tumors, as did 83 percent of those who had tumors that had already spread extensively. On the other hand, only one percent of the patients died of GIST among those with extremely low, low, and moderate risk levels.

Furthermore, the study shows that GIST is considerably more common that scientists previously believed. Worldwide, roughly 15 individuals per million develop the disease each year.

Ulrika Lundin | alfa
Further information:
http://www.sahlgrenska.gu.se/index_eng.jsp

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>